# ELRiSE MDS (NCT07422480)

> A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Lower Risk Myelodysplastic Syndromes (LR-MDS) Who Need Regular Blood Transfusions

No report yet. It can be ordered.

- Drugs tested: elritercept

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT07422480
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: Takeda
- Conditions: Myelodysplastic Syndrome; Anemia
- Interventions: Elritercept; Epoetin Alfa
- Enrollment: 300
- Primary outcome: Proportion of Participants who are RBC Transfusion Independent (RBC-TI) for any Consecutive Greater Than Equal to (≥) 12-Week Period From Day 1 Through 24 Weeks With Concurrent Mean Hemoglobin (Hgb) Increase ≥ 1.5 Grams per Deciliter (g/dL) From Baseline

## Indexed commentary on ELRiSE MDS so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=elrise-mds-nct07422480